Markus Aly

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6033774/publications.pdf

Version: 2024-02-01

56 papers	3,850 citations	236925 25 h-index	168389 53 g-index
59 all docs	59 docs citations	59 times ranked	6918 citing authors

#	Article	IF	Citations
1	The 90â€day causeâ€specific mortality after radical prostatectomy: a nationwide populationâ€based study. BJU International, 2022, 129, 318-324.	2.5	1
2	Mortality in men with castrationâ€resistant prostate cancerâ€”A longâ€term followâ€up of a populationâ€based realâ€world cohort. BJUI Compass, 2022, 3, 173-183.	1.3	12
3	Time to castration-resistant prostate cancer and prostate cancer death according to PSA response in men with non-metastatic prostate cancer treated with gonadotropin releasing hormone agonists. Scandinavian Journal of Urology, 2022, 56, 169-175.	1.0	1
4	Association of 5Î±-Reductase Inhibitors With Prostate Cancer Mortality. JAMA Oncology, 2022, 8, 1019.	7.1	18
5	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nature Genetics, 2021, 53, 65-75.	21.4	264
6	Identifying Prostate Cancer Among Men with Lower Urinary Tract Symptoms. European Urology Open Science, 2021, 24, 11-16.	0.4	2
7	Real world treatment utilization patterns in patients with castration-resistant prostate cancer. Scandinavian Journal of Urology, 2021, 55, 299-306.	1.0	4
8	Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study. European Urology Oncology, 2021, 4, 570-579.	5.4	38
9	MRI-Targeted or Standard Biopsy in Prostate Cancer Screening. New England Journal of Medicine, 2021, 385, 908-920.	27.0	184
10	Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial. Lancet Oncology, The, 2021, 22, 1240-1249.	10.7	83
11	The CanMoRe trial â€“ evaluating the effects of an exercise intervention after robotic-assisted radical cystectomy for urinary bladder cancer: the study protocol of a randomised controlled trial. BMC Cancer, 2020, 20, 805.	2.6	5
12	The effect of sample size on polygenic hazard models for prostate cancer. European Journal of Human Genetics, 2020, 28, 1467-1475.	2.8	14
13	A Genetic Risk Score to Personalize Prostate Cancer Screening, Applied to Population Data. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1731-1738.	2.5	27
14	Lower urinary tract symptoms (LUTS) are not associated with an increased risk of prostate cancer in men 50â€“69 years with PSA â‰¥3â€‰ng/ml. Scandinavian Journal of Urology, 2020, 54, 1-6.	1.0	11
15	Survival in patients diagnosed with castration-resistant prostate cancer: a population-based observational study in Sweden. Scandinavian Journal of Urology, 2020, 54, 115-121.	1.0	36
16	MRI-targeted biopsies in prostate cancer screening and the value of its combination with blood-based risk-prediction: The randomized, diagnostic study STHLM3MRI.. Journal of Clinical Oncology, 2020, 38, TPS378-TPS378.	1.6	0
17	Is there any association between prostate-specific antigen screening frequency and uptake of active surveillance in men with low or very low risk prostate cancer?. BMC Urology, 2019, 19, 73.	1.4	0
18	Salvage radiation therapy following radical prostatectomy in Stockholm County in 2008â€“2016. Journal of Radiation Oncology, 2019, 8, 225-231.	0.7	0

#	Article	IF	Citations
19	Association Between Antidiabetic Medications and Prostate-Specific Antigen Levels and Biopsy Results. JAMA Network Open, 2019, 2, e1914689.	5.9	16
20	Does a novel diagnostic pathway including blood-based risk prediction and MRI-targeted biopsies outperform prostate cancer screening using prostate-specific antigen and systematic prostate biopsies? - protocol of the randomised study STHLM3MRI. BMJ Open, 2019, 9, e027816.	1.9	11
21	Are Prostate Specific-Antigen (PSA) and age associated with the risk of ISUP Grade 1 prostate cancer? Results from 72 996 individual biopsy cores in 6 083 men from the Stockholm3 study. PLoS ONE, 2019, 14, e0218280.	2.5	7
22	Objectively measured mobilisation is enhanced by a new behaviour support tool in patients undergoing abdominal cancer surgery. European Journal of Surgical Oncology, 2019, 45, 1847-1853.	1.0	19
23	A Unified Prostate Cancer Risk Prediction Model Combining the Stockholm3 Test and Magnetic Resonance Imaging. European Urology Oncology, 2019, 2, 490-496.	5.4	13
24	The Stockholm3 blood-test predicts clinically-significant cancer on biopsy: independent validation in a multi-center community cohort. Prostate Cancer and Prostatic Diseases, 2019, 22, 137-142.	3.9	20
25	Preoperative staging using magnetic resonance imaging and risk of positive surgical margins after prostate-cancer surgery. Prostate Cancer and Prostatic Diseases, 2019, 22, 391-398.	3.9	28
26	Poor Follow-up After Elevated Prostate-specific Antigen Tests: A Population-based Cohort Study. European Urology Focus, 2019, 5, 842-848.	3.1	4
27	Time-to-event Outcomes in Men with Nonmetastatic Castrate-resistant Prostate Cancerâ€"A Systematic Literature Review and Pooling of Individual Participant Data. European Urology Focus, 2019, 5, 788-798.	3.1	5
28	Survival in men diagnosed with castration resistant prostate cancer: A population-based observational study in Sweden.. Journal of Clinical Oncology, 2019, 37, e16555-e16555.	1.6	1
29	The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential. European Urology, 2018, 74, 204-210.	1.9	68
30	Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer. Prostate Cancer and Prostatic Diseases, 2018, 21, 57-63.	3.9	134
31	Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. BMJ: British Medical Journal, 2018, 360, j5757.	2.3	153
32	Balancing Overdiagnosis and Early Detection of Prostate Cancer using the Stockholm-3 Model. European Urology Focus, 2018, 4, 385-387.	3.1	9
33	The Stockholm-3 (STHLM3) Model can Improve Prostate Cancer Diagnostics in Men Aged 50â€"69 yr Compared with Current Prostate Cancer Testing. European Urology Focus, 2018, 4, 707-710.	3.1	42
34	Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis. Genome Medicine, 2018, 10, 85.	8.2	94
35	Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging. European Urology, 2018, 74, 722-728.	1.9	70
36	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nature Genetics, 2018, 50, 928-936.	21.4	652

#	Article	IF	Citations
37	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Nature Communications, 2018, 9, 2256.	12.8	88
38	Detection of Prostate Cancer Using a Multistep Approach with Prostate-specific Antigen, the Stockholm 3 Test, and Targeted Biopsies: The STHLM3 MRI Project. European Urology Focus, 2017, 3, 526-528.	3.1	14
39	Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium. British Journal of Cancer, 2017, 117, 734-743.	6.4	7
40	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer Discovery, 2016, 6, 1052-1067.	9.4	157
41	Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation. Nature Communications, 2016, 7, 10979.	12.8	50
42	A population-based study on the association between educational length, prostate-specific antigen testing and use of prostate biopsies. Scandinavian Journal of Urology, 2016, 50, 104-109.	1.0	15
43	The Stockholm-3 (STHLM3) model to improve prostate cancer testing in men 50-69 years compared to current clinical practice.. Journal of Clinical Oncology, 2016, 34, 5050-5050.	1.6	1
44	The risk-based STHLM3 model to improve prostate cancer testing in men 50-69 years: Further health, economic, and clinic evaluation.. Journal of Clinical Oncology, 2016, 34, 36-36.	1.6	0
45	Rapid increase in multidrug-resistant enteric bacilli blood stream infection after prostate biopsy-A 10-year population-based cohort study. Prostate, 2015, 75, 947-956.	2.3	37
46	Prediction of individual genetic risk to prostate cancer using a polygenic score. Prostate, 2015, 75, 1467-1474.	2.3	54
47	Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. Human Molecular Genetics, 2015, 24, 5589-5602.	2.9	67
48	Genome-Wide Association Study of Prostate Cancerâ€“Specific Survival. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1796-1800.	2.5	27
49	Prostate cancer screening in men aged 50â€“69 years (STHLM3): a prospective population-based diagnostic study. Lancet Oncology, The, 2015, 16, 1667-1676.	10.7	308
50	Fine-Mapping the HOXB Region Detects Common Variants Tagging a Rare Coding Allele: Evidence for Synthetic Association in Prostate Cancer. PLoS Genetics, 2014, 10, e1004129.	3.5	34
51	A Genetic Score Can Identify Men at High Risk for Prostate Cancer Among Men With Prostate-Specific Antigen of 1â€“3 ng/ml. European Urology, 2014, 65, 1184-1190.	1.9	32
52	A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nature Genetics, 2014, 46, 1103-1109.	21.4	408
53	Prostate-specific Antigen (PSA) Testing Is Prevalent and Increasing in Stockholm County, Sweden, Despite No Recommendations for PSA Screening: Results from a Population-based Study, 2003â€“2011. European Urology, 2013, 63, 419-425.	1.9	85
54	Polygenic Risk Score Improves Prostate Cancer Risk Prediction: Results from the Stockholm-1 Cohort Study. European Urology, 2011, 60, 21-28.	1.9	117

#	Article	IF	Citations
55	Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nature Genetics, 2011, 43, 785-791.	21.4	265
56	Early detection of prostate cancer with emphasis on genetic markers. Acta OncolÃ³gica, 2011, 50, 18-23.	1.8	18